EA201000002A1 - Полипептид апф2 - Google Patents
Полипептид апф2Info
- Publication number
- EA201000002A1 EA201000002A1 EA201000002A EA201000002A EA201000002A1 EA 201000002 A1 EA201000002 A1 EA 201000002A1 EA 201000002 A EA201000002 A EA 201000002A EA 201000002 A EA201000002 A EA 201000002A EA 201000002 A1 EA201000002 A1 EA 201000002A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- apf2
- polypeptid
- acp2
- dimer
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к рекомбинантному полипептиду АПФ2, где полипептид АПФ2 является димером. Димер специфически формируется из гликозилированных мономеров и используется для получения фармацевтических продуктов с продолжительным периодом полужизни.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0091307A AT505262A1 (de) | 2007-06-12 | 2007-06-12 | Rekombinantes ace2 polypeptid |
EP08450052A EP2108695A1 (de) | 2008-04-08 | 2008-04-08 | Ace2 Polypeptid |
PCT/AT2008/000211 WO2008151347A1 (de) | 2007-06-12 | 2008-06-12 | Ace2 polypeptid |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201000002A1 true EA201000002A1 (ru) | 2010-08-30 |
EA027399B1 EA027399B1 (ru) | 2017-07-31 |
Family
ID=39720296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201000002A EA027399B1 (ru) | 2007-06-12 | 2008-06-12 | Рекомбинантный, гликозилированный, растворимый, димерный, ферментативно активный полипептид апф2 человека и его применение |
Country Status (35)
Country | Link |
---|---|
US (3) | US8586319B2 (ru) |
EP (3) | EP3375872A1 (ru) |
JP (1) | JP5731193B2 (ru) |
KR (2) | KR20160054045A (ru) |
CN (2) | CN104450654A (ru) |
AT (1) | AT505262A1 (ru) |
AU (1) | AU2008261591B2 (ru) |
BR (1) | BRPI0813942B8 (ru) |
CA (1) | CA2692854C (ru) |
CO (1) | CO6270265A2 (ru) |
CR (1) | CR11213A (ru) |
CY (2) | CY1116873T1 (ru) |
DK (2) | DK2155871T3 (ru) |
DO (1) | DOP2009000282A (ru) |
EA (1) | EA027399B1 (ru) |
EG (1) | EG27095A (ru) |
ES (2) | ES2550390T3 (ru) |
HK (2) | HK1255493A1 (ru) |
HR (2) | HRP20151120T1 (ru) |
HU (2) | HUE037877T2 (ru) |
IL (1) | IL202653B (ru) |
LT (1) | LT2543724T (ru) |
MA (1) | MA31472B1 (ru) |
MX (1) | MX2009013472A (ru) |
MY (1) | MY180672A (ru) |
NO (1) | NO2543724T3 (ru) |
NZ (1) | NZ581704A (ru) |
PL (2) | PL2155871T3 (ru) |
PT (2) | PT2543724T (ru) |
RS (2) | RS54340B1 (ru) |
SI (2) | SI2543724T1 (ru) |
TR (1) | TR201808117T4 (ru) |
UA (1) | UA106869C2 (ru) |
WO (1) | WO2008151347A1 (ru) |
ZA (1) | ZA200908751B (ru) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
AT505262A1 (de) * | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
EP2077119A1 (de) * | 2007-12-21 | 2009-07-08 | Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. | Behandlung von Fibrosen und Lebererkrankungen |
AT506632A1 (de) * | 2008-04-09 | 2009-10-15 | Apeiron Biolog Forschungs Und | Behandlung von tumorerkrankungen |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
MX2015000683A (es) | 2012-08-02 | 2015-04-10 | Hoffmann La Roche | Metodo para producir moleculas monomericas y multimericas y uso de las mismas. |
CN112661863A (zh) | 2012-11-20 | 2021-04-16 | 奥普科生物制品有限公司 | 通过连接至***羧基端肽来增加多肽的流体动力学体积的方法 |
WO2014108530A1 (en) * | 2013-01-14 | 2014-07-17 | Apeiron Biologics Ag | Modified ace2 polypeptides |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
EP3988113A1 (en) | 2015-06-19 | 2022-04-27 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
BR112019000610A2 (pt) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | fator vii de coagulação de longa ação e métodos de produção do mesmo |
US11518788B2 (en) * | 2020-07-10 | 2022-12-06 | Avirus, Inc. | Methods and compositions for treating and preventing viral infection |
WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
EP3884957A1 (en) | 2020-03-26 | 2021-09-29 | The University of British Columbia | Methods for treatment of virus and methods for screening of anti-virus reagent using organoids |
EP4138998A4 (en) * | 2020-04-24 | 2024-05-22 | The Administrators Of The Tulane Educational Fund | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE EFFECTS OF INFECTIONS CAUSED BY CORONAVIRUS THAT BIND THE ACE2 RECEPTOR |
CN113667016A (zh) * | 2020-05-15 | 2021-11-19 | 普米斯生物技术(珠海)有限公司 | 一种构建冠状病毒抗体的平台 |
WO2021247675A1 (en) | 2020-06-02 | 2021-12-09 | Ngm Biopharmaceuticals, Inc. | Coronavirus-binding agents and uses thereof |
DE102020207224A1 (de) | 2020-06-09 | 2021-12-09 | Christoph Karle | Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon |
US20230242672A1 (en) * | 2020-06-25 | 2023-08-03 | Gliknik Inc. | Ace2-fc fusion proteins and methods of use |
WO2022008642A1 (en) | 2020-07-08 | 2022-01-13 | Apeiron Biologics Ag | Treatment of sars-cov-2 infection with a combination of targets |
EP4178615A1 (en) * | 2020-07-10 | 2023-05-17 | Biomolecular Holdings LLC | Tetrahedral antibodies |
CN116710560A (zh) * | 2020-08-21 | 2023-09-05 | 西湖大学 | 工程化ace2寡聚物及其用途 |
CN112280764A (zh) * | 2020-11-18 | 2021-01-29 | 通用生物***(安徽)有限公司 | 一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法 |
EP4011387A1 (en) | 2020-12-11 | 2022-06-15 | IMBA-Institut für Molekulare Biotechnologie GmbH | Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2 |
WO2022159433A1 (en) | 2021-01-20 | 2022-07-28 | Singh Biotechnology, Llc | Therapeutics directed against coronavirus |
WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
WO2022207918A1 (en) | 2021-04-02 | 2022-10-06 | Apeiron Biologics Ag | COVID-19 Therapy |
EP4387732A1 (en) | 2021-08-19 | 2024-06-26 | Phenom Pharmaceuticals, inc. | Compositions and methods for treatment of sars cov-2 |
CN113897346A (zh) * | 2021-09-16 | 2022-01-07 | 四川大学 | 能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610497B1 (en) * | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
US6989363B1 (en) * | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
US6194556B1 (en) * | 1997-12-11 | 2001-02-27 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor |
CN1671425B (zh) | 2002-06-19 | 2013-07-10 | 大学保健网 | Ace2激活用于治疗心脏、肺和肾脏疾病及高血压 |
EP1625459A2 (en) | 2002-09-09 | 2006-02-15 | Millenium Pharmaceuticals, Inc. | Crystal structure of angiotensin-converting enzyme-related carboxypeptidase |
EP1723962A1 (en) * | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
AT504443B1 (de) * | 2006-10-19 | 2008-11-15 | Apeiron Biolog Forschungs Und | Verfahren zur bestimmung der aktivität von ace2 |
AT505262A1 (de) * | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
EP2108695A1 (de) | 2008-04-08 | 2009-10-14 | Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. | Ace2 Polypeptid |
AT506258A1 (de) * | 2007-12-18 | 2009-07-15 | Apeiron Biolog Forschungs Und | Behandlung inflammatorischer krankheiten |
AT506632A1 (de) * | 2008-04-09 | 2009-10-15 | Apeiron Biolog Forschungs Und | Behandlung von tumorerkrankungen |
-
2007
- 2007-06-12 AT AT0091307A patent/AT505262A1/de not_active Application Discontinuation
-
2008
- 2008-06-12 CN CN201410412672.3A patent/CN104450654A/zh active Pending
- 2008-06-12 TR TR2018/08117T patent/TR201808117T4/tr unknown
- 2008-06-12 PT PT121651897T patent/PT2543724T/pt unknown
- 2008-06-12 PL PL08756821T patent/PL2155871T3/pl unknown
- 2008-06-12 HU HUE12165189A patent/HUE037877T2/hu unknown
- 2008-06-12 EP EP18161541.0A patent/EP3375872A1/de not_active Withdrawn
- 2008-06-12 DK DK08756821.8T patent/DK2155871T3/en active
- 2008-06-12 ES ES08756821.8T patent/ES2550390T3/es active Active
- 2008-06-12 CA CA2692854A patent/CA2692854C/en active Active
- 2008-06-12 PL PL12165189T patent/PL2543724T3/pl unknown
- 2008-06-12 EP EP08756821.8A patent/EP2155871B1/de active Active
- 2008-06-12 JP JP2010511445A patent/JP5731193B2/ja active Active
- 2008-06-12 NO NO12165189A patent/NO2543724T3/no unknown
- 2008-06-12 WO PCT/AT2008/000211 patent/WO2008151347A1/de active Application Filing
- 2008-06-12 US US12/664,641 patent/US8586319B2/en active Active
- 2008-06-12 ES ES12165189.7T patent/ES2670938T3/es active Active
- 2008-06-12 MY MYPI20095316A patent/MY180672A/en unknown
- 2008-06-12 UA UAA200912888A patent/UA106869C2/uk unknown
- 2008-06-12 BR BRPI0813942A patent/BRPI0813942B8/pt active IP Right Grant
- 2008-06-12 HU HUE08756821A patent/HUE028012T2/en unknown
- 2008-06-12 RS RS20150709A patent/RS54340B1/en unknown
- 2008-06-12 SI SI200831961T patent/SI2543724T1/en unknown
- 2008-06-12 NZ NZ581704A patent/NZ581704A/en unknown
- 2008-06-12 RS RS20180677A patent/RS57292B1/sr unknown
- 2008-06-12 EP EP12165189.7A patent/EP2543724B1/de active Active
- 2008-06-12 AU AU2008261591A patent/AU2008261591B2/en active Active
- 2008-06-12 KR KR1020167011786A patent/KR20160054045A/ko not_active Application Discontinuation
- 2008-06-12 MX MX2009013472A patent/MX2009013472A/es active IP Right Grant
- 2008-06-12 SI SI200831514T patent/SI2155871T1/sl unknown
- 2008-06-12 DK DK12165189.7T patent/DK2543724T3/en active
- 2008-06-12 LT LTEP12165189.7T patent/LT2543724T/lt unknown
- 2008-06-12 PT PT87568218T patent/PT2155871E/pt unknown
- 2008-06-12 CN CN200880100650A patent/CN101796183A/zh active Pending
- 2008-06-12 EA EA201000002A patent/EA027399B1/ru unknown
- 2008-06-12 KR KR1020097027569A patent/KR101682240B1/ko active IP Right Grant
-
2009
- 2009-01-01 ZA ZA200908751A patent/ZA200908751B/xx unknown
- 2009-12-10 IL IL202653A patent/IL202653B/en active IP Right Grant
- 2009-12-10 EG EG2009121812A patent/EG27095A/xx active
- 2009-12-11 DO DO2009000282A patent/DOP2009000282A/es unknown
- 2009-12-30 MA MA32464A patent/MA31472B1/fr unknown
-
2010
- 2010-01-08 CO CO10001879A patent/CO6270265A2/es not_active Application Discontinuation
- 2010-01-12 CR CR11213A patent/CR11213A/es unknown
- 2010-04-28 HK HK18114676.2A patent/HK1255493A1/zh unknown
- 2010-04-28 HK HK10104145.4A patent/HK1136602A1/xx unknown
-
2013
- 2013-09-13 US US14/026,887 patent/US20140099297A1/en not_active Abandoned
-
2015
- 2015-10-23 HR HRP20151120TT patent/HRP20151120T1/hr unknown
- 2015-10-26 CY CY20151100955T patent/CY1116873T1/el unknown
-
2017
- 2017-12-06 US US15/833,243 patent/US10716833B2/en active Active
-
2018
- 2018-05-23 CY CY20181100549T patent/CY1120426T1/el unknown
- 2018-05-30 HR HRP20180856TT patent/HRP20180856T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201000002A1 (ru) | Полипептид апф2 | |
EP4269441A3 (en) | Il-15 and il-15ralpha sushi domain based on modulokines | |
MX2013015393A (es) | Inmunocitosinas basadas en un dominio sushi de il-15 y de il-15ra. | |
EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
WO2013184938A3 (en) | Fusion polypeptides comprising mucin-domain polypeptide linkers | |
NO20071419L (no) | Polypeptidvarianter med endret effektorfunksjon | |
EA200801460A1 (ru) | Рекомбинантные моновалентные антитела и способы их получения | |
MX2017013892A (es) | Inhibidores novedosos del factor xii activado por la enzima (fxiia). | |
ATE428731T1 (de) | Therapeutische antiköper mit reduzierten nebenwirkungen | |
NZ607069A (en) | Modified relaxin polypeptides and their uses | |
RS53455B (en) | OPTIONS DERIVED FROM ActRIIB AND THEIR USE | |
EA201070739A1 (ru) | Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и связанные с ними способы | |
ATE549028T1 (de) | Stabile analoga von glp-1 | |
WO2010034718A8 (fr) | Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire | |
ATE551048T1 (de) | Proteinhydrolysate enthaltende kosmetische zusammensetzungen | |
DE602006020032D1 (de) | Il-21-varianten | |
EA200800535A1 (ru) | Пептиды и соединения, которые связываются с рецептором | |
ATE485379T1 (de) | Zytotoxische ribonukleasevarianten | |
WO2014003538A8 (en) | Rapid specific pathogen free animal | |
EA200801294A1 (ru) | Пептиды-индукторы бактериоцина | |
NZ596501A (en) | Casb7439 constructs | |
EA200800109A1 (ru) | Суправалентные соединения | |
WO2009131698A3 (en) | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF | |
EA201291416A1 (ru) | Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1 | |
CR11059A (es) | Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90 |